Ovarian Cancer, Version 3.2012

Restricted access

These NCCN Guidelines Insights focus on the major updates for the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer by describing how and why the new recommendations were made. The 6 update topics were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials, and include: 1) screening, 2) diagnostic tests for assessing pelvic masses, 3) primary treatment using neoadjuvant chemotherapy, 4) primary adjuvant treatment using bevacizumab in combination with chemotherapy, 5) therapy for recurrent disease, and 6) management of drug/hypersensitivity reactions. These NCCN Guidelines Insights also discuss why some recommendations were not made (eg, panel members did not feel the new data warranted changing the guideline). See “Updates” in the NCCN Guidelines for Ovarian Cancer for a complete list of all the recent revisions.

  • 1

    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:1029.

  • 2

    Howlader N, Noone A, Krapcho M. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations) based on November 2011 SEER data submission. Bethesda, MD: National Cancer Institute; 2012. Available at: http://seer.cancer.gov/csr/1975_2009_pops09/. Accessed October 12, 2012.

    • Search Google Scholar
    • Export Citation
  • 3

    Buys SS, Partridge E, Black A. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305:22952303.

    • Search Google Scholar
    • Export Citation
  • 4

    Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2012: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin, in press.

    • Search Google Scholar
    • Export Citation
  • 5

    Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009;361:170177.

  • 6

    Menon U, Gentry-Maharaj A, Hallett R. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327340.

    • Search Google Scholar
    • Export Citation
  • 7

    Gilbert L, Basso O, Sampalis J. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol 2012;13:285291.

    • Search Google Scholar
    • Export Citation
  • 8

    Drapkin R, von Horsten HH, Lin Y. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65:21622169.

    • Search Google Scholar
    • Export Citation
  • 9

    Nolen B, Velikokhatnaya L, Marrangoni A. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 2010;117:440445.

    • Search Google Scholar
    • Export Citation
  • 10

    Cramer DW, Bast RC Jr, Berg CD. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) 2011;4:365374.

    • Search Google Scholar
    • Export Citation
  • 11

    Anderson GL, McIntosh M, Wu L. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 2010;102:2638.

    • Search Google Scholar
    • Export Citation
  • 12

    Jacob F, Meier M, Caduff R. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol 2011;121:487491.

    • Search Google Scholar
    • Export Citation
  • 13

    Molina R, Escudero JM, Auge JM. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol 2011;32:10871095.

    • Search Google Scholar
    • Export Citation
  • 14

    Van Gorp T, Cadron I, Despierre E. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer 2011;104:863870.

    • Search Google Scholar
    • Export Citation
  • 15

    Montagnana M, Danese E, Ruzzenente O. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med 2011;49:521525.

    • Search Google Scholar
    • Export Citation
  • 16

    Im SS, Gordon AN, Buttin BM. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 2005;105:3541.

  • 17

    Chi DS, Musa F, Dao F. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 2012;124:1014.

    • Search Google Scholar
    • Export Citation
  • 18

    Schorge JO, Bradford LS, Del Carmen MG. Primary cytoreductive surgery for advanced ovarian cancer: is it the past, present, or future? Clin Adv Hematol Oncol 2011;9:912918.

    • Search Google Scholar
    • Export Citation
  • 19

    Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol 2007;25:28732883.

  • 20

    Dewdney SB, Rimel BJ, Reinhart AJ. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists. Gynecol Oncol 2010;119:1821.

    • Search Google Scholar
    • Export Citation
  • 21

    Whitney CW, Spirtos N. Gynecologic Oncology Group Surgical Procedures Manual. Philadelphia, PA: Gynecologic Oncology Group; 2009.

  • 22

    Elattar A, Bryant A, Winter-Roach BA. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2011:CD007565.

    • Search Google Scholar
    • Export Citation
  • 23

    Vergote I, Trope CG, Amant F. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943953.

  • 24

    Vergote I, Trope CG, Amant F. Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. J Clin Oncol 2011;29:40764078.

    • Search Google Scholar
    • Export Citation
  • 25

    Rauh-Hain JA, Rodriguez N, Growdon WB. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol 2012;19:959965.

    • Search Google Scholar
    • Export Citation
  • 26

    Schorge JO, Garrett LA, Goodman A. Cytoreductive surgery for advanced ovarian cancer: quo vadis? Oncology (Williston Park) 2011;25:928934.

  • 27

    Chi DS, Bristow RE, Armstrong DK, Karlan BY. Is the easier way ever the better way? J Clin Oncol 2011;29:40734075.

  • 28

    Rose PG, Nerenstone S, Brady MF. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004;351:24892497.

  • 29

    van der Burg ME, van Lent M, Buyse M. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629634.

    • Search Google Scholar
    • Export Citation
  • 30

    Colombo PE, Mourregot A, Fabbro M. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol 2009;35:135143.

    • Search Google Scholar
    • Export Citation
  • 31

    Hoskins PJ. Which is the better surgical strategy for newly diagnosed epithelial ovarian cancer: primary or interval debulking? Curr Opin Oncol 2011;23:501506.

    • Search Google Scholar
    • Export Citation
  • 32

    Chi DS, Eisenhauer EL, Zivanovic O. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 2009;114:2631.

    • Search Google Scholar
    • Export Citation
  • 33

    Armstrong DK, Bundy B, Wenzel L. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:3443.

  • 34

    Burger RA, Brady MF, Bookman MA. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:24732483.

  • 35

    Perren TJ, Swart AM, Pfisterer J. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:24842496.

  • 36

    Cohn DE, Kim KH, Resnick KE. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011;29:12471251.

    • Search Google Scholar
    • Export Citation
  • 37

    Hensley ML. Big costs for little gain in ovarian cancer. J Clin Oncol 2011;29:12301232.

  • 38

    Parmar MK, Ledermann JA, Colombo N. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:20992106.

    • Search Google Scholar
    • Export Citation
  • 39

    Mantia-Smaldone GM, Edwards RP, Vlad AM. Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies. Cancer Manag Res 2011;3:2538.

    • Search Google Scholar
    • Export Citation
  • 40

    Griffiths RW, Zee YK, Evans S. Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube. Int J Gynecol Cancer 2011;21:5865.

    • Search Google Scholar
    • Export Citation
  • 41

    Markman M. Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. Cancer Manag Res 2011;3:219225.

    • Search Google Scholar
    • Export Citation
  • 42

    Thigpen JT, Aghajanian CA, Alberts DS. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol 2005;96:1018.

  • 43

    Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004;95:18.

    • Search Google Scholar
    • Export Citation
  • 44

    Mutch DG, Orlando M, Goss T. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007;25:28112818.

    • Search Google Scholar
    • Export Citation
  • 45

    Burger RA, Sill MW, Monk BJ. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:51655171.

    • Search Google Scholar
    • Export Citation
  • 46

    Tagawa T, Morgan R, Yen Y, Mortimer J. Ovarian cancer: opportunity for targeted therapy. J Oncol 2012;2012:682480.

  • 47

    Cannistra SA, Matulonis UA, Penson RT. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:51805186.

    • Search Google Scholar
    • Export Citation
  • 48

    Aghajanian C, Blank SV, Goff BA. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:20392045.

    • Search Google Scholar
    • Export Citation
  • 49

    Pujade-Lauraine E, Hilpert F, Weber B. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) [abstract]. J Clin Oncol 2012;30(Suppl 15):Abstract LBA5002.

    • Search Google Scholar
    • Export Citation
  • 50

    Ledermann J, Harter P, Gourley C. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:13821392.

    • Search Google Scholar
    • Export Citation
  • 51

    Buckanovich RJ, Berger R, Sella A. Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): results from a phase II randomized discontinuation trial (RDT) [abstract]. J Clin Oncol 2011;29(Suppl 15):Abstract 5008.

    • Search Google Scholar
    • Export Citation
  • 52

    Cernadas JR, Brockow K, Romano A. General considerations on rapid desensitization for drug hypersensitivity—a consensus statement. Allergy 2010;65:13571366.

    • Search Google Scholar
    • Export Citation
  • 53

    Romano A, Torres MJ, Castells M. Diagnosis and management of drug hypersensitivity reactions. J Allergy Clin Immunol 2011;127:S6773.

  • 54

    Castells MC, Tennant NM, Sloane DE. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122:574580.

    • Search Google Scholar
    • Export Citation
  • 55

    Dizon DS, Sabbatini PJ, Aghajanian C. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 2002;84:378382.

    • Search Google Scholar
    • Export Citation
  • 56

    Sampson HA, Munoz-Furlong A, Campbell RL. Second symposium on the definition and management of anaphylaxis: summary report—second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med 2006;47:373380.

    • Search Google Scholar
    • Export Citation
  • 57

    Manivannan V, Decker WW, Stead LG. Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis. Int J Emerg Med 2009;2:35.

    • Search Google Scholar
    • Export Citation
  • 58

    Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601609.

  • 59

    Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001;19:424436.

    • Search Google Scholar
    • Export Citation
  • 60

    Navo M, Kunthur A, Badell ML. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol 2006;103:608613.

    • Search Google Scholar
    • Export Citation
  • 61

    Markman M, Zanotti K, Peterson G. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003;21:46114614.

    • Search Google Scholar
    • Export Citation
  • 62

    Vandenput I, Van Calster B, Capoen A. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Br J Cancer 2009;101:244249.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 317 285 4
PDF Downloads 45 36 3
EPUB Downloads 0 0 0